Cvfg LLC Has $2.52 Million Stake in Johnson & Johnson $JNJ

Cvfg LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 455.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,290 shares of the company’s stock after purchasing an additional 8,439 shares during the period. Cvfg LLC’s holdings in Johnson & Johnson were worth $2,515,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Arbor Trust Wealth Advisors LLC lifted its stake in Johnson & Johnson by 13.3% in the first quarter. Arbor Trust Wealth Advisors LLC now owns 4,760 shares of the company’s stock valued at $1,164,000 after buying an additional 559 shares in the last quarter. Golden Road Advisors LLC increased its position in shares of Johnson & Johnson by 15.0% during the first quarter. Golden Road Advisors LLC now owns 1,724 shares of the company’s stock worth $421,000 after acquiring an additional 225 shares in the last quarter. Flatrock Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $773,000. Duncker Streett & Co. Inc. lifted its position in Johnson & Johnson by 3.5% in the 1st quarter. Duncker Streett & Co. Inc. now owns 14,724 shares of the company’s stock valued at $3,599,000 after acquiring an additional 494 shares in the last quarter. Finally, Montag A & Associates Inc. lifted its position in Johnson & Johnson by 2.3% in the 1st quarter. Montag A & Associates Inc. now owns 90,103 shares of the company’s stock valued at $22,025,000 after acquiring an additional 2,041 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Argus boosted their price target on Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research report on Wednesday, April 15th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price on the stock in a research note on Wednesday, May 13th. Guggenheim raised their price target on shares of Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. Finally, HSBC set a $290.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Monday. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $258.13.

Johnson & Johnson Stock Down 0.7%

JNJ opened at $257.17 on Friday. The stock’s fifty day simple moving average is $237.07 and its 200 day simple moving average is $233.05. Johnson & Johnson has a 1-year low of $154.80 and a 1-year high of $269.43. The stock has a market cap of $619.07 billion, a PE ratio of 29.73, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the prior year, the business earned $2.77 EPS. Johnson & Johnson’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts expect that Johnson & Johnson will post 11.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.1%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is presently 61.97%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its price target on Johnson & Johnson to $263 from $254, signaling continued support for the stock even as the firm kept a neutral rating. Benzinga report on the price target increase
• Positive Sentiment: Johnson & Johnson backed a new heart failure device trial, keeping investor focus on its medtech pipeline and longer-term growth opportunities in electrophysiology and cardiovascular care. JNJ Backs New Heart Failure Device Trial
• Positive Sentiment: Analysts continued to highlight JNJ as a strong dividend and defensive healthcare name, with several notes pointing to the company’s earnings consistency and attractive income profile. TipRanks dividend aristocrat article
• Neutral Sentiment: Investors are also looking ahead to J&J’s upcoming Q2 earnings report, with previews suggesting the company may again beat expectations, but the market is still waiting for actual results. Zacks Q2 earnings preview
• Negative Sentiment: An Illinois appellate court affirmed a $45 million mesothelioma verdict against Johnson & Johnson and Kenvue tied to talc-related asbestos allegations, renewing legal risk concerns that can weigh on the shares. Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.